An extensible product structure model for product lifecycle management in the make-to-order environment

This paper presents a product structure model with a semantic representation technique that make the product structure extensible for developing product lifecycle management (PLM) systems that is flexible for make-to-order environment. In the make-to-order business context, each product could have a number of variants with slightly different constitutions to fulfill different customer requirements. All the variants of a family have common characteristics and each variant has its specific features. A master-variant pattern is proposed for building the product structure model to explicitly represent common characteristics and specific features of individual variants. The model is capable of enforcing the consistency of a family structure and its variant structure, supporting multiple product views, and facilitating the business processes. A semantic representation technique is developed that enables entity attributes to be defined and entities to be categorized in a neutral and semantic format. As a result, entity attributes and entity categorization can be redefined easily with its configurable capability for different requirements of the PLM systems. An XML-based language is developed for semantically representing entities and entity categories. A prototype as a proof-of-concept system is presented to illustrate the capability of the proposed extensible product structure model

On a free boundary problem for a two-species weak competition system

[[abstract]]We study a Lotka–Volterra type weak competition model with a free boundary in a one-dimensional habitat. The main objective is to understand the asymptotic behavior of two competing species spreading via a free boundary. We also provide some sufficient conditions for spreading success and spreading failure, respectively. Finally, when spreading successfully, we provide an estimate to show that the spreading speed (if exists) cannot be faster than the minimal speed of traveling wavefront solutions for the competition model on the whole real line without a free boundary.[[incitationindex]]SCI[[booktype]]紙本[[booktype]]電子

Partial Wave Analysis of J/ψ→γ(K+K−π+π−)J/\psi \to \gamma (K^+K^-\pi^+\pi^-)

BES data on $J/\psi \to \gamma (K^+K^-\pi^+\pi^-)$ are presented. The $K^*\bar K^*$ contribution peaks strongly near threshold. It is fitted with a broad $0^{-+}$ resonance with mass $M = 1800 \pm 100$ MeV, width $\Gamma = 500 \pm 200$ MeV. A broad $2^{++}$ resonance peaking at 2020 MeV is also required with width $\sim 500$ MeV. There is further evidence for a $2^{-+}$ component peaking at 2.55 GeV. The non-$K^*\bar K^*$ contribution is close to phase space; it peaks at 2.6 GeV and is very different from $K^{*}\bar{K^{*}}$.Comment: 15 pages, 6 figures, 1 table, Submitted to PL

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362